| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum | 1 | Y | 0 Induction SST | 1273 | 790 | 119 | 63 | 32 | 9 | 1 | 09/24/2018 | 334 | 139 |
| 790 | 119 | 63 | 32 | 9 | 1 | |||||||||
| 2 | Y | 1 Standard Systemic Therapy Only | 277 | 39 | 16 | 7 | 2 | 0 | 09/24/2018 | |||||
| 2 SST + Surgery/RT | 279 | 41 | 19 | 9 | 3 | 0 | ||||||||
| 556 | 80 | 35 | 16 | 5 | 0 | |||||||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | 1 | Y | 0 Pre-Rand. SST | 332 | 140 | 53 | 27 | 13 | 6 | 3 | 03/08/2021 | 211 | 76 | |
| 140 | 53 | 27 | 13 | 6 | 3 | |||||||||
| 2 | Y | 1 Systemic Immuno. Only | 50 | 22 | 12 | 4 | 2 | 0 | 03/08/2021 | |||||
| 2 Nephrectomy + Systemic Immuno. | 41 | 14 | 5 | 1 | 1 | 1 | ||||||||
| 91 | 36 | 17 | 5 | 3 | 1 | |||||||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | 1 | Y | 1 Physician Choice Chemo | 184 | 11 | 3 | 3 | 3 | 2 | 0 | 06/28/2021 | 187 | 68 | |
| 2 Eribulin | 8 | 1 | 0 | 0 | 0 | 0 | ||||||||
| 3 Eribulin + Gemcitabine | 8 | 1 | 1 | 1 | 0 | 0 | ||||||||
| 27 | 5 | 4 | 4 | 2 | 0 | |||||||||
| S2200-pRCC, Adv, Cabo +/- Atezo | 1 | Y | 1 Cabozantinib Only | 200 | 8 | 7 | 4 | 3 | 1 | 1 | 03/24/2023 | 141 | 62 | |
| 2 Cabozantinib + Atezolizumab | 8 | 7 | 5 | 4 | 2 | 0 | ||||||||
| 16 | 14 | 9 | 7 | 3 | 1 | |||||||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | 1 | Y | 1 Carboplatin + Surgery | 44 | 1 | 1 | 1 | 1 | 0 | 0 | 03/01/2024 | 119 | 37 | |
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| Yes | A031702-GU, Mets, Cabozantinib+Nivo+Ipi (ICONIC) | 1 | E | Total Registrations | 26 | 2 | 0 | 0 | 0 | 0 | 08/09/2019 | 227 | 92 | |
| 26 | 2 | 0 | 0 | 0 | 0 | |||||||||
| A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo | 1 | E | Total Registrations | 126 | 20 | 13 | 8 | 4 | 0 | 10/02/2019 | 273 | 130 | ||
| 126 | 20 | 13 | 8 | 4 | 0 | |||||||||
| 2 | E | Total Registrations | 84 | 13 | 4 | 4 | 1 | 0 | 10/02/2019 | |||||
| 84 | 13 | 4 | 4 | 1 | 0 | |||||||||
| A031803-Blad, NMIBC, Gemcitabine + MK-3475 | 1 | E | Total Registrations | 43 | 9 | 3 | 3 | 2 | 0 | 03/18/2020 | 131 | 56 | ||
| 43 | 9 | 3 | 3 | 2 | 0 | |||||||||
| A032103-Urothelial, All Stg, MRD-Based Adj Tx | 0 | E | Total Registrations | 1 | 1 | 1 | 1 | 0 | 0 | 03/19/2024 | 12 | 13 | ||
| 1 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EA8171-PROS, newly diagnosed, mpMRI for pre-op stagi | 1 | E | Total Registrations | 87 | 3 | 0 | 0 | 0 | 0 | 02/11/2019 | 92 | 48 | ||
| 87 | 3 | 0 | 0 | 0 | 0 | |||||||||
| NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide | 1 | E | Total Registrations | 13 | 7 | 4 | 3 | 1 | 0 | 09/25/2020 | 226 | 82 | ||
| 13 | 7 | 4 | 3 | 1 | 0 | |||||||||
| NRGGU011-Pros, Dbl Blinded RT +/- Androgen Dep Tx | 1 | E | Total Registrations | 9 | 8 | 6 | 1 | 0 | 0 | 03/29/2023 | 199 | 72 | ||
| 9 | 8 | 6 | 1 | 0 | 0 | |||||||||
| NRGGU012-Renal, Stg IV, Stereo Abl Rad Therapy | 1 | E | Total Registrations | 2 | 2 | 2 | 1 | 0 | 0 | 01/10/2024 | 171 | 56 | ||
| 2 | 2 | 2 | 1 | 0 | 0 | |||||||||
| No | A031701-Bladder, ddGC for MIBC with DDR Tumor Alt | 1 | E | Total Registrations | 20 | 6 | 2 | 1 | 1 | 0 | 12/17/2018 | 137 | 50 | |
| 20 | 6 | 2 | 1 | 1 | 0 | |||||||||
| 2 | E | Total Registrations | 17 | 5 | 3 | 1 | 1 | 0 | 12/17/2018 | |||||
| 17 | 5 | 3 | 1 | 1 | 0 | |||||||||
| 3 | E | Total Registrations | 2 | 0 | 0 | 0 | 0 | 0 | 12/17/2018 | |||||
| 2 | 0 | 0 | 0 | 0 | 0 | |||||||||
| A031801-GU, mRCC, Cabozantinib +/- Radium-223 | 1 | E | Total Registrations | 14 | 5 | 3 | 1 | 0 | 0 | 11/06/2020 | 99 | 39 | ||
| 14 | 5 | 3 | 1 | 0 | 0 | |||||||||
| EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT | 1 | E | Total Registrations | 12 | 2 | 0 | 0 | 0 | 0 | 04/25/2019 | 29 | 14 | ||
| 12 | 2 | 0 | 0 | 0 | 0 | |||||||||
| EA8191-Pros, Local vs Systemic Thrpy | 0 | E | Total Registrations | 29 | 13 | 7 | 2 | 1 | 0 | 09/24/2021 | 185 | 62 | ||
| 29 | 13 | 7 | 2 | 1 | 0 | |||||||||
| 1 | E | Total Registrations | 29 | 13 | 7 | 2 | 1 | 0 | 09/24/2021 | |||||
| 29 | 13 | 7 | 2 | 1 | 0 | |||||||||
| EA8192-Blad, High Grade UTUC, Durv + Chemo | 1 | E | Total Registrations | 3 | 1 | 1 | 1 | 0 | 0 | 02/23/2022 | 146 | 54 | ||
| 3 | 1 | 1 | 1 | 0 | 0 | |||||||||
| EA8212-Blad, NMIBC, BRIDGE | 1 | E | Total Registrations | 104 | 89 | 54 | 34 | 11 | 1 | 02/07/2023 | 126 | 68 | ||
| 104 | 89 | 54 | 34 | 11 | 1 | |||||||||
| NRGGU009-Pros, PREDICT-RT | 1 | E | Total Registrations | 49 | 32 | 18 | 8 | 5 | 0 | 03/01/2022 | 420 | 156 | ||
| 49 | 32 | 18 | 8 | 5 | 0 | |||||||||
| 2 | E | Total Registrations | 46 | 32 | 18 | 7 | 4 | 0 | 03/01/2022 | |||||
| 46 | 32 | 18 | 7 | 4 | 0 | |||||||||
| NRGGU010-Pros, Parallel De-Intens & Intens Trials | 1 | E | Total Registrations | 34 | 21 | 11 | 4 | 2 | 0 | 01/03/2022 | 421 | 157 | ||
| 34 | 21 | 11 | 4 | 2 | 0 | |||||||||
| 2 | E | Total Registrations | 31 | 19 | 9 | 3 | 1 | 0 | 01/03/2022 | |||||
| 31 | 19 | 9 | 3 | 1 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| A032103 Urothelial, All Stg, MRD-Based Adj Tx | 1 Registration | 09-Jan-24 | 12 | 13 |
| 2 Re-Registration | 09-Jan-24 | 12 | 13 | |
| EA8134 Penile, Local Adv, ILND +/- Chemo or ChemoRT | 2 Randomization2 | 08-Sep-17 | 29 | 14 |